Theranostics combines targeted imaging and therapy in a single, highly precise approach. By using radioactive tracers that selectively bind to cancer cells, we can first visualize where the disease is, then deliver focused radiation from within the body. This reduces damage to healthy tissue and can improve outcomes for patients with advanced or difficult-to-treat tumors. Our nuclear medicine department delivers the below therapies:
- Lutetium-177 PSMA Therapy
A targeted treatment for metastatic prostate cancer that delivers Lu-177 radiation directly to PSMA-expressing cancer cells throughout the body.
- Actinium-225 Therapy
It uses an alpha-emitting radionuclide linked to a targeting molecule to deliver very short-range, high-energy radiation directly to marker-expressing cancer cells, aiming to intensively damage tumor DNA while limiting exposure to surrounding healthy tissue.
- Radioactive Iodine (RAI) Therapy
Used mainly for thyroid diseases, RAI is absorbed by thyroid cells to eliminate overactive or malignant tissue with minimal impact on other organs.
- Transarterial Radioembolization (TARE)
Tiny radioactive beads are delivered through the liver’s arteries to irradiate tumors from the inside while preserving healthy liver tissue.